MedWatch

Novo Nordisk is making progress toward stabilizing Wegovy supply

Danish pharmaceutical company Novo Nordisk is hard at work with stabilizing the supply of its obesity drug Wegovy, which has been in high demand in the US since its June launch.

Photo: Novo Nordisk / PR

Novo Nordisk is currently making progress in securing its supply of the obesity drug Wegovy, the company reports on its website.

This means that doses of 0.25 mg, 0.5 mg and 1 mg are being replenished, while ongoing delays are still expected for doses of 1.7 mg and 2.4 mg for the rest of the year.

Read the whole article

Get 14 days free access.
No credit card required.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

"Real world" patient data documents the long-term effects of ALK vaccines

In the largest study ever of its kind, patient data from the "real world" documents the long-term effects of up to nine years of ALK vaccines. Up until now, it has not been possible to demonstrate these in ordinary clinical studies where the follow-up period is shorter, and the new knowledge could be a turning point in ALK's dialog about prices and subsidies with authorities and payers. 

Further reading

Related articles

Latest news

See all jobs